🕵️ Nextcure, Inc. ($NXTC)
SEC insider & ownership activity, last 12 months · CIK 1661059 · every row links its SEC filing
Insider buy value was withheld pending verification over the last 12 months. No red-flag 8-Ks in the window.
Insider flow
1 buyer, value withheld pending verification (13 lots) · 1 seller, $185K (1 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 13 | value withheld pending verification | 0 | – | Jul 31, 2026 |
| Simcere Zaiming, Inc. | 0 | – | 1 | $185K | Aug 10, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 15.8% | 13G | Aug 14, 2026 | filing ↗ | |
| Daniel Schneeberger | 15.8% | 13G | Aug 14, 2026 | filing ↗ | |
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | 12.7% | 13G | Aug 19, 2025 | filing ↗ | |
| Ikarian Capital, LLC | 10.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Neil Shahrestani | 10.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Simcere Zaiming, Inc. | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Simcere Pharmaceutical Group Limited | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Ren Jinsheng | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Tang Renhong | 9.4% | 13G | May 6, 2026 | filing ↗ | |
| Adage Capital Management, L.P. | 7.7% | 13G | Aug 12, 2026 | filing ↗ | |
| Robert Atchinson | 7.7% | 13G | Aug 12, 2026 | filing ↗ | |
| Phillip Gross | 7.7% | 13G | Aug 12, 2026 | filing ↗ | |
| Affinity Healthcare Fund, LP | 7.2% | 13G | Nov 14, 2025 | filing ↗ | |
| Sofinnova Management IX, L.L.C. ("SM IX") | 7.1% | 13D | Dec 19, 2025 | filing ↗ | |
| DR. James I. Healy ("HEALY") | 7.1% | 13D | Dec 19, 2025 | filing ↗ | |
| Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | 13D | Dec 19, 2025 | filing ↗ | |
| Affinity Asset Advisors, LLC | 6.4% | 13G | Aug 13, 2026 | filing ↗ | |
| Michael Cho | 6.4% | 13G | Aug 13, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Sep 3, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 3, 2026 | filing ↗ |
| Earnings (2.02) | Aug 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 6, 2026 | filing ↗ |
| Material agreement (1.01) | Jul 14, 2026 | filing ↗ |
| Exit or disposal costs (2.05) | Jul 14, 2026 | filing ↗ |
| Change of control (5.01) | Jul 14, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 14, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 14, 2026 | filing ↗ |
| Other events (8.01) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 18, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 18, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 1, 2026 | filing ↗ |
| Other events (8.01) | Jun 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 1, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Earnings (2.02) | Mar 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 5, 2026 | filing ↗ |
| Earnings (2.02) | Jan 23, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 23, 2026 | filing ↗ |
| Other events (8.01) | Jan 23, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 23, 2026 | filing ↗ |
| Other events (8.01) | Dec 19, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 19, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 12, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Nov 12, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 12, 2025 | filing ↗ |